|
EP2945940B1
(en)
*
|
2013-01-16 |
2020-07-15 |
The Regents of The University of Michigan |
Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer
|
|
US9993472B2
(en)
|
2014-01-28 |
2018-06-12 |
Unity Biotechnology, Inc. |
Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
|
|
CN106456699B
(zh)
|
2014-05-05 |
2021-07-02 |
生物风险投资有限责任公司 |
作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法
|
|
CA2955972A1
(en)
|
2014-07-22 |
2016-01-28 |
Bioventures, Llc. |
Compositions and methods for selectively depleting senescent cells
|
|
US20180000816A1
(en)
*
|
2015-02-06 |
2018-01-04 |
Unity Biotechnology, Inc. |
Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
|
|
JP2018508569A
(ja)
*
|
2015-02-06 |
2018-03-29 |
ユニティ バイオテクノロジー インコーポレイテッド |
老化関連状態の治療における化合物および使用
|
|
US11111259B2
(en)
|
2015-12-18 |
2021-09-07 |
Unity Biotechnology, Inc. |
Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
|
|
IL295472B2
(en)
|
2016-03-28 |
2024-10-01 |
Presage Biosciences Inc |
Pharmaceutical combinations for the treatment of cancer
|
|
CN109152933B
(zh)
*
|
2016-04-21 |
2022-12-02 |
生物风险投资有限责任公司 |
诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
|
|
CN106177955B
(zh)
*
|
2016-08-18 |
2018-03-16 |
广州威溶特医药科技有限公司 |
Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
|
|
WO2018098534A1
(en)
*
|
2016-12-02 |
2018-06-07 |
Garvan Institute Of Medical Research |
Methods of treating cancer and reagents thereof
|
|
US20200354336A9
(en)
*
|
2017-08-11 |
2020-11-12 |
Unity Biotechnology, Inc. |
Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
|
|
CN111372598A
(zh)
*
|
2017-08-11 |
2020-07-03 |
联合生物科技公司 |
使用消除衰老细胞的药剂治疗诸如黄斑变性,青光眼,和糖尿病性视网膜病变等眼科状况
|
|
WO2019033122A1
(en)
*
|
2017-08-11 |
2019-02-14 |
Unity Biotechnology, Inc. |
TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
|
|
US10588916B2
(en)
*
|
2017-10-31 |
2020-03-17 |
Unity Biotechnology, Inc. |
Technology to inhibit vascular changes that lead to vision loss in the eye
|
|
AU2018357829B2
(en)
|
2017-12-30 |
2019-09-26 |
Unity Biotechnology, Inc. |
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
|
|
IL316472A
(en)
|
2018-01-10 |
2024-12-01 |
Recurium Ip Holdings Llc |
Benzamide compounds
|
|
ES3041854T3
(en)
|
2018-01-22 |
2025-11-17 |
Bioventures Llc |
Bcl-2 proteins degraders for cancer treatment
|
|
CN112437772B
(zh)
|
2018-04-29 |
2023-11-21 |
百济神州有限公司 |
Bcl-2抑制剂
|
|
WO2019213151A1
(en)
*
|
2018-04-30 |
2019-11-07 |
Unity Biotechnology |
Phosphonamidates that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
|
|
WO2019221755A1
(en)
|
2018-05-18 |
2019-11-21 |
Bioventures, Llc |
Piperlongumine analogues and uses thereof
|
|
US11478469B2
(en)
|
2018-07-31 |
2022-10-25 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases
|
|
CA3095699A1
(en)
|
2018-07-31 |
2020-02-06 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
|
|
AU2019315466B2
(en)
|
2018-07-31 |
2022-05-19 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
|
|
TW202019421A
(zh)
|
2018-07-31 |
2020-06-01 |
大陸商蘇州亞盛藥業有限公司 |
Bcl-2/Bcl-xL抑制劑與化療藥物的組合及其應用
|
|
CN110772521A
(zh)
*
|
2018-07-31 |
2020-02-11 |
苏州亚盛药业有限公司 |
Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
|
|
US11903950B2
(en)
|
2018-08-22 |
2024-02-20 |
Newave Pharmaceutical Inc. |
BCL-2 inhibitors
|
|
US11872237B2
(en)
*
|
2018-12-28 |
2024-01-16 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Pharmaceutical composition and preparation method thereof
|
|
TWI731540B
(zh)
*
|
2019-01-04 |
2021-06-21 |
大陸商蘇州亞盛藥業有限公司 |
製備磺胺類藥物的方法
|
|
CN111410666B
(zh)
*
|
2019-01-04 |
2021-02-19 |
苏州亚盛药业有限公司 |
一种制备磺胺类化合物的工艺
|
|
TWI770503B
(zh)
*
|
2019-05-13 |
2022-07-11 |
大陸商蘇州亞盛藥業有限公司 |
用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
|
|
WO2021000899A1
(en)
*
|
2019-07-02 |
2021-01-07 |
Ascentage Pharma (Suzhou) Co., Ltd. |
A PHARMACEUTICAL COMBINATION CONTAINING mTOR INHIBITOR AND USE THEREOF
|
|
US12370197B2
(en)
*
|
2019-07-31 |
2025-07-29 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
|
|
WO2021066873A1
(en)
|
2019-10-03 |
2021-04-08 |
Newave Pharmaceutical Inc. |
Condensed heterocycles as bcl-2 inhibitors
|
|
CN112707900B
(zh)
*
|
2019-10-24 |
2022-06-10 |
上海科技大学 |
蛋白降解剂及其在疾病治疗中的应用
|
|
WO2021083135A1
(en)
|
2019-10-28 |
2021-05-06 |
Beigene, Ltd. |
Bcl-2 INHIBITORS
|
|
WO2021104442A1
(en)
*
|
2019-11-27 |
2021-06-03 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
|
|
CN118542872A
(zh)
*
|
2019-12-04 |
2024-08-27 |
苏州亚盛药业有限公司 |
药物组合及其用途
|
|
CN114786654A
(zh)
*
|
2019-12-11 |
2022-07-22 |
密执安大学评议会 |
用于全身递送Bcl-2和Bcl-xL拮抗剂的组合物和方法
|
|
BR112022012283A2
(pt)
|
2019-12-20 |
2022-08-30 |
Recurium Ip Holdings Llc |
Combinações
|
|
CN113350281B
(zh)
*
|
2020-03-02 |
2023-08-15 |
苏州亚盛药业有限公司 |
载药聚合物胶束及其制剂和制备方法
|
|
WO2021204060A1
(en)
*
|
2020-04-10 |
2021-10-14 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combinations of bcl-2/bcl-xl inhibitors and related uses
|
|
CN116969937B
(zh)
|
2020-04-15 |
2026-03-24 |
百济神州(苏州)生物科技有限公司 |
Bcl-2抑制剂
|
|
WO2021233948A1
(en)
|
2020-05-19 |
2021-11-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat a pathogen lung infection
|
|
EP4175644A1
(en)
|
2020-07-06 |
2023-05-10 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
|
|
WO2022012481A1
(en)
*
|
2020-07-13 |
2022-01-20 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Crystalline or Amorphous form of Bcl-2/Bcl-xL inhibitor compound or its salts
|
|
CN114053288B
(zh)
*
|
2020-07-31 |
2024-11-19 |
苏州亚盛药业有限公司 |
肺部疾病治疗的组合物和方法
|
|
MX2023005447A
(es)
*
|
2020-11-10 |
2023-09-25 |
Unity Biotechnology Inc |
Inhibidor de sales sólidas cristalinas de meglumina de bcl y métodos de elaboración y uso de estos.
|
|
WO2022111647A1
(en)
*
|
2020-11-27 |
2022-06-02 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Formulation combination containing freeze-dried formulation and reconstituted solvent, preparation method and application thereof
|
|
US12454674B2
(en)
|
2020-12-04 |
2025-10-28 |
University Of Notre Dame Du Lac |
Method of encapsulating single cells utilizing an alternating current electrospray
|
|
JP2024528174A
(ja)
*
|
2021-08-02 |
2024-07-26 |
アセンテージ ファーマ(スーチョウ)カンパニー,リミティド |
医薬組合せおよびその使用
|
|
TW202415653A
(zh)
*
|
2022-08-02 |
2024-04-16 |
大陸商北京星奇原生物科技有限公司 |
Bcl-xl降解化合物
|
|
CN119923390A
(zh)
*
|
2022-09-06 |
2025-05-02 |
西藏海思科制药有限公司 |
一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用
|
|
WO2024245312A1
(en)
*
|
2023-05-30 |
2024-12-05 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Bcl-2/bcl-xl protein degrader and use thereof
|
|
WO2025087879A2
(en)
|
2023-10-23 |
2025-05-01 |
Institut National de la Santé et de la Recherche Médicale |
Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia
|
|
WO2026114258A1
(en)
*
|
2024-11-27 |
2026-06-04 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Bcl-2/bcl-xl protein degrader and use thereof
|